How to Increase Girth Size Permanently: The Retention Science Explained
Introduction: Why ‘Permanent’ Means Something Different Depending on the Method
The word “permanent” is one of the most abused terms in the entire field of male enhancement. Providers use it loosely, marketing pages use it liberally, and the result is a landscape where a high-intent reader cannot reliably compare one clinic’s claim against another. When a man is seriously considering a procedure, that ambiguity is not just frustrating; it is a genuine barrier to making a sound decision.
The concern behind that decision is legitimate and widely documented. A BJUI study of 15,521 men found that only 55% were satisfied with their penis size. A peer-reviewed 2024 study confirmed that poor genital self-image correlates directly with higher scores on both depression and anxiety inventories, along with reduced erectile function. For accomplished, otherwise confident men, this is not vanity; it is a measurable quality-of-life issue.
The central thesis of this article is straightforward: permanence in girth enhancement exists on a clinical spectrum, and understanding where each method sits on that spectrum is the only way to make an informed decision. That spectrum has three tiers: hyaluronic acid (HA) filler, which is semi-permanent with high retention lasting 18 to 24 months or more; PMMA-based filler, which is near-permanent through a lasting collagen scaffold; and the surgical silicone implant, which is fully permanent but carries the highest risk profile.
Every claim here is grounded in peer-reviewed urological literature, AUA position statements, and Journal of Sexual Medicine data, not clinic marketing copy. By the end, the reader will have the clinical vocabulary to evaluate any provider’s permanence claim, including the 80 to 90% permanent improvement figure cited by practices such as Stoller Medical Group.
Defining the Permanence Spectrum: A Framework Most Providers Don’t Give You
Permanent girth gain is not a binary outcome; it is a spectrum, and each position on it is defined by the biology of the material used and the way the body responds to that material. Understanding this framework is the single most important step before evaluating any provider’s claims.
Only three methods are supported by peer-reviewed urological literature to produce measurable, lasting girth gains: HA-based fillers, PMMA-based fillers, and the Penuma silicone implant. Everything else falls outside the evidence base. The three sections below unpack each tier in depth.
Tier 1: Semi-Permanent: Hyaluronic Acid (HA) Filler
HA filler is the most clinically studied non-surgical approach, with the strongest short-to-medium-term evidence base of any method. A 2024 Journal of Sexual Medicine study of 155 men showed an average girth increase of 1.8 cm across multiple HA treatments, rising to 2.952 cm for men who received four or more treatments, illustrating the compounding effect of staged sessions.
The December 2023 AUA News reported that HA injections can durably enhance flaccid and erect penile diameter by an average of 2.27 ± 1.26 cm at four weeks post-procedure, with a promising safety profile and no inflammatory signs or serious adverse reactions in prospective studies.
Longevity deserves honesty. HA is technically semi-permanent because the body gradually metabolizes hyaluronic acid over 18 to 24 months. However, UroFill clinical data supports a 90% retention rate at two to four years, and a USPTO-published study of 121 patients showed over 92% reported no or only mild filler loss at a 21.1-month mean follow-up. HA is classified as semi-permanent rather than permanent precisely because the material is bioabsorbable by design. That same property is what makes it reversible, which is a significant safety advantage.
HA fillers produce measurable gains in both flaccid and erect states, unlike some surgical options that primarily enhance flaccid appearance. Because HA longevity increases with repeated injections as the tissue adapts, subsequent top-ups require less volume. A proactive maintenance schedule every 12 to 18 months is more cost-effective than waiting for full reabsorption.
Tier 2: Near-Permanent: PMMA-Based Filler (Bellafill®)
PMMA (polymethylmethacrylate) is the closest non-surgical option to permanent girth enhancement. The mechanism is biological: PMMA microspheres are not metabolized by the body. Instead, they act as a permanent scaffold that stimulates lasting collagen formation around each microsphere.
A large-scale Bellafill clinical study of 1,008 patients over five years showed an 87% retention rate, the strongest long-term non-surgical retention data available. PMMA is classified as “near-permanent” rather than fully permanent because, while the microspheres persist indefinitely, some collagen remodeling occurs over time, and the 87% figure reflects that.
PMMA’s permanence is also its primary risk. Because it cannot be dissolved or reversed, placement precision is critical, and the risk of nodule or granuloma formation rises when the material is injected into unprepared tissue. This is exactly why the HA-to-PMMA conversion pathway (covered later) exists as a clinical protocol: it is a risk-mitigation approach grounded in tissue preparation science, not an upsell strategy. PMMA-based approaches also typically require 40 or more days of recovery, compared to roughly 10 days for HA-based protocols, a meaningful difference for men with active professional lives.
Tier 3: Fully Permanent: The Penuma Silicone Implant
The Penuma, also marketed as Himplant, is the only FDA 510(k)-cleared subcutaneous silicone device for cosmetic penile girth enhancement. Multi-institutional data shows patients added an average of 3.4 cm to penile girth, a 37% increase and the largest single-procedure gain of any available method.
The complication data deserves equal weight: infection (0.6%), seroma (1.2%), and erosion (3.6%). Erosion requiring implant removal is a meaningful risk for a fully permanent device. A 2025 Journal of Sexual Medicine complication study noted that the Sexual Medicine Society of North America recommends Penuma implants only be performed on IRB-approved research protocols, given concerns about severe complications in young patients with no underlying sexual dysfunction. The Penuma also requires circumcision, which disqualifies a significant portion of candidates, and it primarily enhances flaccid girth; erect gains are less consistent than with filler-based approaches.
Fully permanent is not synonymous with best outcome. It means the highest commitment, the highest risk profile, and the least reversibility. For a man not yet certain of his desired size, starting here is the highest-stakes decision on the spectrum.
The 80–90% Permanent Retention Figure: What the Biology Actually Means
When a clinic states “80 to 90% permanent improvement,” what does that number actually represent, and why is it the correct clinical expectation rather than a marketing hedge?
The answer lies in a two-phase retention model. Phase 1 (weeks 1 to 4) involves apparent volume reduction that is not filler loss at all; it is the dispersal of the anesthetic fluid (the tumescent solution) used during the procedure. That fluid temporarily inflates the treated area and dissipates within the first four weeks. Phase 2 (months 1 to 24 and beyond) represents the actual filler that has integrated into the tissue. This is the stable, retained volume, and it is this phase the 80 to 90% figure describes.
Translated practically: if a treatment delivers a 1.5-inch girth increase immediately post-procedure, the 10 to 20% early-phase reduction means the stable, long-term result will be approximately 1.2 to 1.35 inches. That remains a clinically significant and visibly noticeable outcome. The USPTO data reinforces this precisely: over 92% of 121 patients reported no or only mild filler loss at 21.1 months, and over 85% were completely or mostly satisfied, numbers that align cleanly with an 80 to 90% retention claim.
Subsequent sessions retain even better. Once tissue is primed by an initial treatment, the structural environment for filler integration becomes more favorable. This is why the staged protocol is not merely about adding volume incrementally; it is about building a progressively more stable retention environment.
This is also why filler type matters enormously. The AUA and Urology Care Foundation explicitly state that subcutaneous fat injection for girth “has not been shown to be safe or efficacious.” A documented fatal fat embolism in a 30-year-old man following penile fat injection underscores that not all injectable approaches carry the same evidence base or safety profile.
The Staged Injection Protocol: Why Multiple Sessions Compound Permanence
The staged protocol is the clinical standard, not a commercial strategy to inflate session counts. It is a medically grounded approach to optimizing safety, symmetry, and long-term retention.
Providers cap single sessions at approximately 20 ml to avoid complications including lymphatic overload, asymmetry, and migration. Each session delivers roughly 0.25 to 0.5 inches of girth increase. Between sessions, the penile tissue remodels around the integrated filler, creating a more structurally stable substrate for the next injection. This tissue adaptation mechanism is exactly why men who received four or more treatments in the Journal of Sexual Medicine study averaged 2.952 cm of girth increase, nearly double the single-session average.
Staging also enables symmetry refinement. The provider assesses the distribution of each prior treatment and makes precise adjustments at every subsequent session, producing far more proportional, natural-looking results than a single large-volume procedure could. Post-procedure, patients avoid aggressive sexual activity for four to six weeks to minimize mechanical stress on filler, which is the primary cause of asymmetry and migration rather than natural breakdown.
The staged approach and the 80 to 90% retention claim are directly connected: the protocol is designed so each session builds on the retention established by the last, compounding permanence across the treatment course. Most patients reach their goals over two to three sessions, with follow-up typically scheduled two to three months after the initial treatment.
The HA-to-PMMA Conversion Pathway: The Most Sophisticated Non-Surgical Permanence Strategy Available
This is the clinical angle almost entirely absent from competitor content: a two-phase protocol that combines the advantages of both HA and PMMA while mitigating the primary risk of each.
Phase 1 (HA foundation): The patient begins with HA filler to establish desired size, shape, and symmetry. Because HA is reversible and dissolvable with hyaluronidase, this phase allows both patient and provider to dial in the aesthetic outcome with zero long-term commitment. If the patient is unsatisfied with the size or distribution, adjustments happen before any permanent material is introduced.
Phase 2 (PMMA layering): Once the outcome is confirmed through HA, PMMA is layered over the established scaffold. The prepared tissue, already adapted to the presence of filler, provides a substantially more favorable environment for PMMA integration, reducing the nodule and granuloma risk associated with injecting PMMA into unprepared tissue. Some providers market this protocol under names like FusionThick or BellaThick.
The permanence outcome is elegant: the PMMA layer creates a lasting collagen scaffold that maintains the size and shape established during the HA phase, effectively converting a semi-permanent result into a near-permanent one without the recovery burden or risk profile of surgical implantation. Emerging research points to the next evolution. A 2025 PMC case report described a dual-phase HA plus PLLA (poly-L-lactic acid) approach that combines immediate HA volume with gradual PLLA neocollagenesis, achieving a 0.63-inch flaccid girth gain maintained at six months.
This pathway answers the question most high-intent readers are actually asking: how to get permanent results without committing to surgery before knowing exactly what they want.
What to Expect: Realistic Outcomes Across the Permanence Spectrum
Expected girth gains by method: HA filler averages 1.8 to 2.5 cm across multiple sessions; PMMA/Bellafill holds an 87% retention rate at five years; the Penuma implant averages 3.4 cm, a 37% increase.
Context matters. Per AUA data, the average man has a flaccid circumference of 9.31 cm and an erect circumference of 11.66 cm. Most men seeking enhancement fall within the normal size range, confirming that the driver of demand is psychological confidence rather than anatomical deficiency. Even modest, well-retained gains can produce meaningful improvements in self-image.
On flaccid versus erect gains: HA fillers deliver measurable results in both states; the Penuma primarily enhances flaccid appearance; PMMA results are comparable to HA in both. On recovery: HA-based protocols allow return to sexual activity within seven to 10 days and full recovery in roughly 10 days, versus 40 or more days for PMMA-only approaches and significantly longer for surgery. On candidacy: Penuma requires circumcision; PMMA is best for patients who have already established their outcome through HA; HA filler is the broadest-access entry point with the most favorable safety profile for first-time candidates.
The satisfaction data is clinically meaningful. A 2025 Journal of Sexual Medicine study reported 89% patient-reported satisfaction for HA filler, and the USPTO study showed over 85% completely or mostly satisfied at 21.1 months.
Methods That Don’t Deliver Permanent Gains: What the Evidence Actually Says
High-intent readers have almost certainly encountered at-home and non-clinical methods, and they deserve authoritative closure on them.
Pills, supplements, jelqing, vacuum pumps, and extender devices have no peer-reviewed clinical evidence supporting permanent girth gains. The EAU guidelines explicitly caution against most of these. Fat injection warrants specific attention: the AUA and Urology Care Foundation state that subcutaneous fat injection for girth “has not been shown to be safe or efficacious,” and a fatal fat embolism in a 30-year-old man following penile fat injection is on record. That is not a marginal risk; it is a documented fatality in a young, healthy patient. For a detailed comparison of evidence-based injectable options versus fat grafting, see our penile filler vs. fat grafting overview.
It is also worth noting that the FDA has not approved any injectable specifically for penile size enhancement, meaning all injectable approaches, including HA and PMMA, are used off-label. This is standard practice in aesthetic medicine, but it underscores the importance of provider expertise and material selection.
The absence of evidence for at-home methods is not a gap in the research; it is the research. Peer-reviewed urological literature has examined these approaches and found them wanting. A provider who recommends evidence-based methods over unproven ones is demonstrating clinical integrity, not limiting options.
Evaluating a Provider: The Clinical Questions That Separate Expert Care from Risk
For the reader now ready to evaluate specific providers, the following questions represent practical due diligence.
- What filler material do you use, and why? A provider should explain the specific material, its evidence base, retention profile, and reversibility. Vague answers are a red flag.
- Do you use a staged protocol? A provider offering single-session dramatic results without staging is prioritizing volume over safety. The rationale (lymphatic overload risk, tissue adaptation, symmetry refinement) is well established.
- What is your complication management protocol? Any provider should have a clear plan for migration, asymmetry, and, with HA, dissolution via hyaluronidase.
- How many procedures have you performed? Volume of experience matters in a procedure requiring precise knowledge of penile vasculature and tissue planes. Stoller Medical Group’s 15,000-plus procedures is a meaningful benchmark.
- What does your follow-up protocol look like? A provider who does not schedule follow-up at two to three months is performing a procedure, not managing a result.
Board certification and hospital-grade sterility protocols are non-negotiable minimum standards, not differentiators. Multi-location accessibility, meanwhile, is a genuine convenience for patients who want geographic proximity without sacrificing clinical quality.
Stoller Medical Group’s Approach: How the 80–90% Permanent Improvement Claim Fits the Evidence Framework
This section offers a practical application of everything above: a clinical case study in how one provider’s claims map to the evidence framework.
Stoller Medical Group uses Belefil, a hyaluronic acid-based medical-grade dermal filler, placing it squarely in the HA tier: semi-permanent with high retention, reversible, and backed by the strongest non-surgical evidence base. Using the two-phase retention model, the 80 to 90% permanent improvement claim represents the stable, integrated filler volume after the early anesthetic fluid dispersal phase. It is consistent with UroFill clinical data (90% retention at two to four years) and the USPTO study (92% reporting no or only mild filler loss at 21.1 months).
The 10-day recovery claim is a meaningful differentiator. Where PMMA-based approaches require 40 or more days, the HA-based protocol allows return to sexual activity within seven to 10 days, which matters considerably for professional men with demanding schedules. The staged approach, with follow-up two to three months after initial treatment and optional periodic touch-ups, aligns precisely with the clinical standard for compounding retention and refining symmetry.
On pricing: the procedure starts at $7,500, with cost structured by syringe. Most men begin with a minimum of 10 syringes, and the average first procedure involves approximately 15 syringes. Final cost scales with the patient’s desired outcome and anatomy. That structure reflects the precision and material quality involved, not a commodity service. The 15,000-plus procedures performed represents a volume-of-experience benchmark that is clinically substantive; at that scale, a provider has encountered and managed the full range of anatomical variation. Five locations (Manhattan, Long Island, Albany, Pennsylvania, and Minnesota) provide practical accessibility across the Northeast and Midwest, and free consultations lower the barrier to a professional in-person evaluation. Patients interested in reading firsthand accounts can review Belefil penile enhancement reviews from prior patients.
Conclusion: Permanence Is a Spectrum — Choose Your Position on It Deliberately
Permanence in girth enhancement is not a binary claim; it is a spectrum defined by material biology, ranging from HA (semi-permanent, high retention, reversible) through PMMA (near-permanent, lasting collagen scaffold) to surgical implant (fully permanent, highest risk, irreversible).
The 80 to 90% retention figure is a clinically grounded expectation, not a marketing hedge. It reflects the stable, integrated filler volume after early anesthetic fluid dispersal, supported by multiple peer-reviewed studies. The HA-to-PMMA conversion pathway stands as the most sophisticated non-surgical permanence strategy available for men who want long-term results without committing to surgery before confirming what they want.
The psychological dimension is real. Research clearly links dissatisfaction with genital self-image to depression and anxiety, even in men within the normal anatomical range. Addressing that through evidence-based, clinically supervised enhancement is a legitimate and increasingly mainstream medical decision. The reader now has the vocabulary to evaluate any provider’s permanence claim, ask the right questions, and choose deliberately.
Ready to Evaluate Your Options with a Board-Certified Expert?
For a reader who now understands the permanence spectrum, a consultation is not a sales step; it is the logical next action to determine where a specific anatomy and set of goals fit on that spectrum.
Stoller Medical Group offers free, no-pressure consultations designed specifically to assess individual anatomy, discuss realistic outcomes, and build a customized staged treatment plan tailored to the patient’s goals. With five locations across Manhattan, Long Island, Albany, Pennsylvania, and Minnesota, and more than 15,000 procedures performed, the practice has seen the full range of patient presentations and outcomes.
Schedule a free consultation to receive a personalized assessment of which position on the permanence spectrum is right for you.
